02:14 PM EDT, 06/17/2025 (MT Newswires) -- CERo Therapeutics ( CERO ) said Tuesday that the US Food and Drug Administration has granted orphan drug designation for its lead drug candidate, CER-1236, for acute myeloid leukemia.

Shares jumped over 220% as intraday trading volume advanced to over 51.2 million from a daily average of about 101,000.

Acurx Pharmaceuticals ( ACXP ) said its lead antibiotic candidate, ibezapolstat, is ready to advance to international phase 3 clinical trials to treat patients with C. difficile infection.

Shares soared over 130% as intraday trading volume surged to more than 309 million from a daily average of roughly 182,000.

Eli Lilly ( LLY ) said that it agreed to acquire Verve Therapeutics ( VERV ) for up to about $1.3 billion to advance gene-editing therapies for cardiovascular disease.

Verve shares soared 78%, with intraday trading volume of more than 72.5 million against a daily average of about 3.49 million.

Price: 22.04, Change: +15.18, Percent Change: +220.97